Below is the breakdown of how much the makers of Betaseron (a drug used to treat multiple sclerosis) raised the price of the drug. Over the past 3-4 years, the price for a month supply of Betaseron went up by 78%. The patient’s copay remained the same through this price inflation because seldom do companies want to raise copayments of medicines to their workers. Instead, the cost is transferred back to everyone as a rise in their monthly insurance premium. At the end of the day, American companies pay for these outrageous price increases and ultimately hurts their competitive advantage in the marketplace. The drug company profit motive overwhelms the overall interests of society.